Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

mayne pharma inc. - fluorouracil (unii: u3p01618rt) (fluorouracil - unii:u3p01618rt) - fluorouracil cream is recommended for the topical treatment of multiple actinic or solar keratoses. in the 5% strength, it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. safety and efficacy in other indications have not been established. the diagnosis should be established prior to treatment, since this method has not been proven effective in other types of basal cell carcinomas. with isolated, easily accessible basal cell carcinomas, surgery is preferred since success with such lesions is almost 100%. the success rate with fluorouracil cream is approximately 93%, based on 113 lesions in 54 patients. eighty-eight lesions treated with the cream produced 7 failures. fluorouracil cream may cause fetal harm when administered to a pregnant woman. there are no adequate and well-controlled studies in pregnant women with either the topical or the parenteral forms of fluorouracil. one birth defe

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

accord healthcare inc. - fluorouracil (unii: u3p01618rt) (fluorouracil - unii:u3p01618rt) - fluorouracil cream usp is recommended for the topical treatment of multiple actinic or solar keratoses. in the 5% strength, it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. safety and efficacy in other indications have not been established. the diagnosis should be established prior to treatment, since this method has not been proven effective in other types of basal cell carcinomas. with isolated, easily accessible basal cell carcinomas, surgery is preferred since success with such lesions is almost 100%. the success rate with fluorouracil cream usp is approximately 93%, based on 113 lesions in 54 patients. eighty-eight lesions treated with the cream produced 7 failures. fluorouracil cream may cause fetal harm when administered to a pregnant woman. there are no adequate and well-controlled studies in pregnant women with either the topical or the parenteral forms of fluorouracil. one bi

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - fluorouracil (unii: u3p01618rt) (fluorouracil - unii:u3p01618rt) - fluorouracil cream usp is recommended for the topical treatment of multiple actinic or solar keratoses. in the 5% strength, it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. safety and efficacy in other indications have not been established. the diagnosis should be established prior to treatment, since this method has not been proven effective in other types of basal cell carcinomas. with isolated, easily accessible basal cell carcinomas, surgery is preferred since success with such lesions is almost 100%. the success rate with fluorouracil cream usp is approximately 93%, based on 113 lesions in 54 patients. eighty-eight lesions treated with the cream produced 7 failures. fluorouracil cream may cause fetal harm when administered to a pregnant woman. there are no adequate and well-controlled studies in pregnant women with either the topical or the parenteral forms of fluorouracil. one bi

Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - fluorouracil 5%{relative};  ;   - topical cream - 5% w/w - active: fluorouracil 5%{relative}     excipient: methyl hydroxybenzoate polysorbate 60 propyl hydroxybenzoate propylene glycol purified water stearyl alcohol white soft paraffin - dp-fluorouracil is used for the topical treatment of superficial pre-malignant and malignant skin lesions; keratoses including senile, actinic and arsenical forms, keratoa canthoma; bowen's disease; superficial basal-cell carcinoma.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - fluorouracil, quantity: 5 % w/w - cream - excipient ingredients: methyl hydroxybenzoate; polysorbate 60; purified water; propylene glycol; propyl hydroxybenzoate; stearyl alcohol; white soft paraffin - solar and senile keratoses, bowen's disease.

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

spear dermatology products - fluorouracil (unii: u3p01618rt) (fluorouracil - unii:u3p01618rt) - fluorouracil 5 mg in 1 g

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

northstar rx llc - fluorouracil (unii: u3p01618rt) (fluorouracil - unii:u3p01618rt) - fluorouracil is recommended for the topical treatment of multiple actinic or solar keratoses. in the 5% strength, it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. safety and efficacy in other indications have not been established. the diagnosis should be established prior to treatment, since this method has not been proven effective in other types of basal cell carcinomas. with isolated, easily accessible basal cell carcinomas, surgery is preferred since success with such lesions is almost 100%. the success rate with fluorouracil cream and solution is approximately 93%, based on 113 lesions in 54 patients. twenty-five lesions treated with the solution produced 1 failure and 88 lesions treated with the cream produced 7 failures. fluorouracil may cause fetal harm when administered to a pregnant woman. there are no adequate and well-controlled studies in pregnant women with either the top

Kanada - anglų - Health Canada

sandoz canada incorporated - fluorouracil - solution - 50mg - fluorouracil 50mg - antineoplastic agents

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

bausch health us, llc - fluorouracil (unii: u3p01618rt) (fluorouracil - unii:u3p01618rt) - fluorouracil 5 mg in 1 g - carac is indicated for the topical treatment of multiple actinic or solar keratoses of the face and anterior scalp. fluorouracil may cause fetal harm when administered to a pregnant woman. fluorouracil is contraindicated in women who are or may become pregnant. if this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. no adequate and well-controlled studies have been conducted in pregnant women with either topical or parenteral forms of fluorouracil. one birth defect (ventricular septal defect) and cases of miscarriage have been reported when fluorouracil was applied to mucous membrane areas. multiple birth defects have been reported in the fetus of a patient treated with intravenous fluorouracil. animal reproduction studies have not been conducted with carac. fluorouracil, the active ingredient, has been shown to be teratogenic in mice, rats, and hamsters when administered parenterally at doses grea

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

pierre fabre pharmaceuticals, inc. - fluorouracil (unii: u3p01618rt) (fluorouracil - unii:u3p01618rt) - fluorouracil 40 mg in 1 g - tolak (fluorouracil) cream is indicated for the topical treatment of actinic keratosis lesions of the face, ears, and/or scalp. tolak cream is contraindicated: - during pregnancy [see warnings and precautions (5.5, 8.1)] - in patients with dihydropyrimidine dehydrogenase (dpd) deficiency [see warnings and precautions (5.6)] tolak cream may cause fetal harm when administered during pregnancy and is contraindicated in women who are pregnant. if this drug is used during pregnancy, or if the patient becomes pregnant while using this drug, the patient should be apprised of the potential hazard to the fetus. tolak cream is contraindicated in patients with dihydropyrimidine dehydrogenase (dpd) deficiency. teratogenic effects: pregnancy category x [see contraindications (4.1)] . cases of miscarriage and birth defects (including cleft lip and cleft palate) have been reported wh